Although malignant melanoma is the best example, if MM cases that are highly dependent on the RAS-RAF-MEK-ERK pathway can be identified at the first examination, combining BTZ or LEN with a pan-RAF inhibitor in these cases from an early stage is recommended. The gene discussed is RAF1; the disease is Miyoshi myopathy.